Literature DB >> 9288451

Aqueous humor induces transforming growth factor-beta (TGF-beta)-producing regulatory T-cells.

A W Taylor1, P Alard, D G Yee, J W Streilein.   

Abstract

PURPOSE: The intraocular microenvironment is an immune-privileged site where immunogenic inflammation is suppressed. Suppression of immunogenic inflammation has been associated with immunosuppressive factors found in aqueous humor produced by ocular tissues. To further understand the mechanisms suppressing immunogenic inflammation in the eye, we have examined the production of lymphokines by primed T-cells activated in the presence of aqueous humor.
METHODS: Enriched in vivo primed T-cells were T-cell receptor-stimulated in the presence of fresh aqueous humor. The culture supernatant was assayed for IFN-gamma and IL-4 by sandwich ELISA. TGF-beta production by T-cells stimulated in the presence of aqueous humor was assayed by a TGF-beta bioassay of the culture supernatant and by quantitative RT-PCR for TGF-beta 1 mRNA expression. Aqueous humor-treated T-cells were assayed for their capacity to suppress IFN-gamma production by stimulated, primed T-cells.
RESULTS: Aqueous humor-enhanced proliferation but irreversibly suppressed production of both IFN-gamma and IL-4 by in vitro-activated, in vivo-primed T-cells. Aqueous humor induced in vivo primed T-cells to produce TGF-beta in vitro, and these TGF-beta-producing T-cells suppressed IFN-gamma production by other T-cells activated in co-cultures.
CONCLUSIONS: Aqueous humor alters the functional program of TCR-ligand-activated, primed T-cells, converting the cells to TGF-beta-producing regulatory cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288451     DOI: 10.1076/ceyr.16.9.900.5043

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  36 in total

Review 1.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model.

Authors:  Taisuke Ito; Natsuho Ito; Albrecht Bettermann; Yoshiki Tokura; Masahiro Takigawa; Ralf Paus
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

4.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

5.  Retinal laser burn disrupts immune privilege in the eye.

Authors:  Hong Qiao; Kenyatta Lucas; Joan Stein-Streilein
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

6.  A new look at immune privilege of the eye: dual role for the vision-related molecule retinoic acid.

Authors:  Ru Zhou; Reiko Horai; Mary J Mattapallil; Rachel R Caspi
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

Review 7.  Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates.

Authors:  Ravid Shechter; Anat London; Michal Schwartz
Journal:  Nat Rev Immunol       Date:  2013-03       Impact factor: 53.106

8.  Rabies virus ocular disease: T-cell-dependent protection is under the control of signaling by the p55 tumor necrosis factor alpha receptor, p55TNFR.

Authors:  S Camelo; J Castellanos; M Lafage; M Lafon
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

9.  Following EAU recovery there is an associated MC5r-dependent APC induction of regulatory immunity in the spleen.

Authors:  Darren J Lee; Andrew W Taylor
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-17       Impact factor: 4.799

Review 10.  Negative regulators that mediate ocular immune privilege.

Authors:  Andrew W Taylor; Tat Fong Ng
Journal:  J Leukoc Biol       Date:  2018-02-12       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.